The latest price target for ALX Oncology Holdings (NASDAQ:ALXO) was reported by UBS on August 16, 2024. The analyst firm set a price target for $4.00 expecting ALXO to rise to within 12 months (a possible 86.92% upside). 19 analyst firms have reported ratings in the last year.

The latest analyst rating for ALX Oncology Holdings (NASDAQ:ALXO) was provided by UBS, and ALX Oncology Holdings maintained their buy rating.

The last upgrade for ALX Oncology Holdings Inc happened on December 8, 2023 when Jefferies raised their price target to $18. Jefferies previously had a hold for ALX Oncology Holdings Inc.

The last downgrade for ALX Oncology Holdings Inc happened on March 8, 2024 when Stifel changed their price target from $10 to $14 for ALX Oncology Holdings Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ALX Oncology Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ALX Oncology Holdings was filed on August 16, 2024 so you should expect the next rating to be made available sometime around August 16, 2025.

While ratings are subjective and will change, the latest ALX Oncology Holdings (ALXO) rating was a maintained with a price target of $25.00 to $4.00. The current price ALX Oncology Holdings (ALXO) is trading at is $2.14, which is out of the analyst’s predicted range.